However, undesirable side effects, such as severe hepatic steatosis, hypertriglyceridemia, and off-target stimulation of the farnesoid X receptor (FXR) [83] and pregnane X receptor (PXR) [84], have greatly tempered the prospect of this compound’s general clinical use. This evidence concerns the gene NR1I2 and fatty liver disease.